Overview

Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
FSGS is an immunologic disorder wherein circulating immune proteins cause damage to the kidneys and progressive injury and scarring. Corticosteroid therapy is occasionally, but not nearly universally, successful in reducing proteinuria, and when patients respond, they have a favorable prognosis. The investigators believe that ACTH therapy (H.P. Acthar Gel) can provide a more rapid, well tolerated reduction in glomerular injury.
Phase:
Phase 4
Details
Lead Sponsor:
Stanford University
Collaborator:
Mallinckrodt
Treatments:
Adrenocorticotropic Hormone